Coherus BioSciences (CHRS) Scheduled to Post Quarterly Earnings on Thursday

Coherus BioSciences (NASDAQ:CHRS) is set to issue its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.33). The business had revenue of $77.06 million during the quarter, compared to analysts’ expectations of $102.00 million. During the same quarter last year, the firm posted ($0.89) earnings per share. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus BioSciences Stock Up 1.9 %

Shares of CHRS stock traded up $0.03 during trading hours on Tuesday, hitting $1.35. 956,456 shares of the company were exchanged, compared to its average volume of 2,752,781. The firm has a fifty day moving average of $1.64 and a 200 day moving average of $2.07. Coherus BioSciences has a 1 year low of $1.24 and a 1 year high of $5.47. The firm has a market cap of $154.31 million, a PE ratio of -1.69 and a beta of 0.60.

Analyst Ratings Changes

CHRS has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Coherus BioSciences in a research note on Monday. StockNews.com cut Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Friday, July 26th. Robert W. Baird lowered their price target on Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Monday, July 1st. Finally, Truist Financial cut their price objective on Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, May 13th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.